Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
8d agoen
From the article
Conditions : PIK3CA-Related Overgrowth Spectrum (PROS); Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) Interventions : Drug: Alpelisib; Drug: Fulvestrant; Drug: Trastuzumab; Drug: Pertuzumab; Drug: Letrozole Sponsors : Novartis Pharmaceuticals Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Samjin Pharm Launches Breast Cancer Treatment Fulveserd
Seoul Economic Daily·3d ago
Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
This article examines Amgen's legal battle over PCSK9 cholesterol drugs, specifically their patent dispute with Sanofi and Regeneron. Amgen
alexkesin.com·9mo agoGlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK·17y ago
AstraZeneca to pull breast cancer and endometriosis drug Zoladex from Australian market in November
AstraZeneca is removing the breast cancer and endometriosis drug Zoladex from Australia's Pharmaceutical Benefits Scheme (PBS) and private m
theguardian.com·28d agoOvarian Stimulation With Letrozole Shows No Short-Term Molecular Impact on Breast Tumors 2026
OncoDaily·8h ago
Acute versus Long-term anti-GPVI Treatment: From Receptor Blockade to Partial Downregulation
communities.springernature.com·15h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.